Episode Details
Back to Episodes
Daily Roundup | Replimune Wins FDA Approval for Melanoma Drug After Two Rejections
Published 1 month, 1 week ago
Description
FDA approved Replimune's Tudriqev for advanced melanoma after two rejections - and over its own reviewers' written objections. Plus Moderna's mRNA flu vaccine mFlusiva clears for adults 50 and older with a split label, Iovance jumps 34% on record Amtagvi revenue and a 56% gross margin, and Tarsus buys Alkeus for up to $800 million for gildeuretinol in Stargardt disease. Melanoma, influenza, cell therapy and inherited retinal disease in a single Thursday. Visit us at thepharmacloseout.com.